Page last updated: 2024-08-24

irinotecan and Central Nervous System Neoplasm

irinotecan has been researched along with Central Nervous System Neoplasm in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (38.46)29.6817
2010's6 (46.15)24.3611
2020's2 (15.38)2.80

Authors

AuthorsStudies
Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA1
Bishop, MW; Borinstein, SC; DuBois, SG; Hingorani, P; Krystal, J; Laetsch, TW; Levy, DE; Mascarenhas, L; Mo, G; Muscal, JA; Ogawa, C; Shahir, A; Slotkin, EK; Weigel, BJ; Wright, J1
Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K1
Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G1
Jin, J; Joo, KM; Kang, W; Kim, KH; Kim, SU; Lee, JI; Nam, DH; Seol, HJ; Yang, H1
Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW1
Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K1
Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G1
Matsko, MV1
Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Houghton, PJ; Keir, S; Moschel, RC; Pegg, AE1
Buster, WP; Gruber, ML1
Prados, M1
Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Miller, LL; Nelson, G1

Reviews

1 review(s) available for irinotecan and Central Nervous System Neoplasm

ArticleYear
Temozolomide in combination with other cytotoxic agents.
    Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide

2001

Trials

7 trial(s) available for irinotecan and Central Nervous System Neoplasm

ArticleYear
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Cancer medicine, 2023, Volume: 12, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Humans; Irinotecan; Maximum Tolerated Dose; Metformin; Neoplasm Recurrence, Local; Neoplasms; Sarcoma, Ewing; Temozolomide; Vincristine

2023
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
    Cancer medicine, 2021, Volume: 10, Issue:3

    Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ifosfamide; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Salvage Therapy; Tissue Distribution; Vincristine

2021
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:11

    Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult

2013
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide

2014
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
    Journal of neuro-oncology, 2008, Volume: 90, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Immunosuppressive Agents; Irinotecan; Male; Middle Aged; Survival Analysis; Thalidomide

2008
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
    American journal of clinical oncology, 2004, Volume: 27, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome

2004
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    American journal of clinical oncology, 2002, Volume: 25, Issue:2

    Topics: Adult; Antineoplastic Agents; Camptothecin; Central Nervous System Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors

2002

Other Studies

5 other study(ies) available for irinotecan and Central Nervous System Neoplasm

ArticleYear
Genetically-engineered human neural stem cells with rabbit carboxyl esterase can target CNS lymphoma.
    Anticancer research, 2013, Volume: 33, Issue:12

    Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Bystander Effect; Camptothecin; Carboxylesterase; Central Nervous System Neoplasms; DNA Primers; Genetic Engineering; Humans; Irinotecan; Lymphoma; Male; Mice; Mice, Inbred BALB C; Neural Stem Cells; Rabbits; Reverse Transcriptase Polymerase Chain Reaction

2013
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
    Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome

2011
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
    Anti-cancer drugs, 2012, Volume: 23, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome

2012
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
    Voprosy onkologii, 2012, Volume: 58, Issue:3

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Drug Administration Schedule; Glioma; Humans; Irinotecan; Temozolomide

2012
O6-benzylguanine-mediated enhancement of chemotherapy.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Dacarbazine; DNA; Enzyme Inhibitors; Female; Guanine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Synthesis Inhibitors; Temozolomide

2002